Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)

NCT05312918 is registered in ClinicalTrials.gov with ANRS, Emerging Infectious Diseases as lead sponsor.

NCT NCT05312918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05312918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)
Lead sponsor
ANRS, Emerging Infectious Diseases
Phase
Observational
Overall status
Unknown status
Start date
May 31, 2022
Completion date
October 31, 2024
Enrollment
603 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections